Skip to content
AnalystLens

Labcorp Holdings 8-K Report, Financial Results (Feb 17, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 17, 2026
Period End
February 17, 2026
Security
LH
In the record · 2016–202610-K1310-Q338-K382

LH filed 13 annual reports (10-K), 33 quarterly reports (10-Q) and 382 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jun ’19Jun ’19
  2. Material agreement8-K · May ’21May ’21
  3. Deal closed8-K · Jul ’23Jul ’23
  4. Material agreement8-K · Jan ’25Jan ’25

01—Abstract

Summary

Summary of the 8-K filed February 17, 2026. Cited figures are marked; the original filing is the authoritative source.

Labcorp Holdings Inc. furnished its fourth-quarter and full-year 2025 results and 2026 guidance under Item 2.02 of this Form 8-K, via Exhibit 99.1, a press release.

Full-year 2025 revenue was $13.95 billiona, up from $13.01 billion, and the filing states full-year revenue growth of 7.2%, with organic growth of 4.4%. Full-year diluted EPS was $10.46 versus $8.84, and adjusted EPS was $16.44 versus $14.57. Fourth-quarter revenue was $3.52 billion versus $3.33 billion, and fourth-quarter adjusted EPS was $4.07 versus $3.45.

Fourth-quarter GAAP diluted EPS of $1.98b was lower than the adjusted figure, and fourth-quarter restructuring and other charges rose to $110.8 million from $11.4 million. Full-year free cash flow was $1.21 billion, compared with $1.10 billion in 2024. Fourth-quarter free cash flow fell to $490.3 million from $665.1 million, which the company attributed to working capital timing.

The company ended the year with $532.3 millionc of cash and $5.58 billion of total debt. It invested $582.0 million in acquisitions during 2025, repurchased $450.0 million of stock, and paid $240.7 million in dividends. The board declared a quarterly dividend of $0.72 per share, payable March 12, 2026.

For 2026, Labcorp guided to revenue of $14.61 billion to $14.79 billiond (midpoint growth of 5.4%), adjusted EPS of $17.55 to $18.25 (midpoint growth of 8.9%), and free cash flow of $1.24 billion to $1.36 billion (midpoint growth of 7.8%). The filing also highlights a planned 500,000 square foot Central Laboratory facility in Indiana, with construction expected to begin later in 2026, and a backlog of $8.72 billion at year-end, up 9.2%.

02—Key points

Key Highlights

  1. Full-year 2025 revenue of $13.95 billion, up from $13.01 billion, with stated growth of 7.2% and organic growth of 4.4%
  2. Full-year adjusted EPS of $16.44 versus $14.57; full-year diluted EPS of $10.46 versus $8.84
  3. Fourth-quarter revenue of $3.52 billion versus $3.33 billion; fourth-quarter adjusted EPS of $4.07 versus $3.45
  4. Full-year free cash flow of $1.21 billion versus $1.10 billion; fourth-quarter free cash flow declined to $490.3 million from $665.1 million due to working capital timing
  5. 2026 guidance: revenue of $14.61–$14.79 billion, adjusted EPS of $17.55–$18.25, and free cash flow of $1.24–$1.36 billion
  6. Fourth-quarter restructuring and other charges of $110.8 million, up from $11.4 million a year earlier
  7. Capital returns in 2025 included $450.0 million of share repurchases and $240.7 million of dividends; the Q1 2026 quarterly dividend is $0.72 per share

03—Questions

Frequently Asked Questions

  1. How did Labcorp perform in the fourth quarter and full year of 2025?

    Fourth-quarter revenue was $3.52 billion versus $3.33 billion, and operating income was $267.6 million versus $216.5 million. Full-year revenue was $13.95 billion versus $13.01 billion, with stated growth of 7.2%. Full-year diluted EPS was $10.46 versus $8.84, and adjusted EPS was $16.44 versus $14.57.

  2. What is Labcorp's 2026 financial guidance?

    Labcorp guided to 2026 enterprise revenue of $14.61 billion to $14.79 billion, adjusted EPS of $17.55 to $18.25, and free cash flow of $1.24 billion to $1.36 billion. The filing states midpoint growth of 5.4% for revenue, 8.9% for adjusted EPS, and 7.8% for free cash flow. Guidance assumes foreign exchange rates as of December 31, 2025, and includes the estimated impact of planned capital allocation.

  3. Why did free cash flow decline in the fourth quarter?

    Fourth-quarter free cash flow was $490.3 million versus $665.1 million a year earlier. The company stated the decrease was primarily driven by working capital timing. Full-year free cash flow still increased to $1.21 billion from $1.10 billion.

  4. What did the company do with its capital in 2025?

    During 2025, Labcorp invested $582.0 million in acquisitions, repurchased $450.0 million of common stock, and paid $240.7 million in dividends. It ended the year with $532.3 million of cash and equivalents and $5.58 billion of total debt. The company also declared a quarterly dividend of $0.72 per share, payable March 12, 2026.

  5. What are the notable operational developments mentioned in the filing?

    The company reported 13 acquisition or closing transactions with health systems and regional or local laboratories in 2025, and launched more than 130 new tests. It also announced a strategic investment in a 500,000 square foot Central Laboratory facility in Indiana, with construction expected to begin later in 2026. Year-end backlog was $8.72 billion, up 9.2%.

04—Continue

← View all 8-K filings